德国Nova疟疾检测试剂盒

疟疾是一种危及生命的疾病,这是由原生动物引起的疟原虫spp。传播是由疟蚊传播,但可以通过输血也发生。人类可以通过四个不同种类的疟原虫感染间日疟原虫、恶性疟原虫,p .那三日疟原虫。

感染恶性疟原虫可以是致命的。恶性疟原虫和间日疟原虫是zui常见的类型。该病主要发生在热带和亚热带地区。

疟疾感染诱发特定抗体的生产。一般发生后几天内可以检测到血液中的寄生虫。特定抗体的浓度成正比,感染的强度和持续时间。抗体的检测比直接检测更敏感的病原体和独立地位的感染。*在人类感染的特定抗体水平下降后快速恢复。??比之下抗体水平下降缓慢(在2 ?3年)重新感染的人进入非流行地区。

NovaLisa吗?疟疾抗体试验是一种快速、敏感的酶免疫分析法检测特定的免疫球蛋白和IgM抗体疟原虫。

微型板块上涂了一层重组抗原的恶性疟原虫和间日疟原虫。p .那和p .疟疾也发现由于抗原不同疟原虫物种之间的相似性。

感染的诊断则需要通过:

显微镜:直接探测和识别病原体是可能的,但不确定

血清学:特定抗体基于ELISA-technique的决心

NovaLisaTM疟疾ELISA:

NovaLisaTM疟疾ELISA用于抗体的定性测定疟原虫在人类血清或血浆(柠檬酸)。

主要的试验

定性immunoenzymatic疟原虫抗体的确定是基于ELISA(酶联免疫吸附试验)技术。

微量滴定板井重新板与疟原虫抗原结合相应抗体的标本。洗井后删除所有的样品材料hoseradish过氧化物酶(合)贴上人类免疫球蛋白和IgM共轭。这种共轭结合捕获Plasmodium-specific抗体。

免疫complecx结合共轭形成可视化通过添加Tetramethylbenzidine(*)衬底,使一个蓝色的反应产物。这个产品的强度成正比的Plasmodium-specific标本中的抗体。硫酸添加到停止反应。这产生一个黄色端点的颜色。吸光度在450 nm读取使用ELISA microwell板读者。

重组抗原:

重组CSP和MSP1蛋白质从间日疟原虫和恶性疟原虫

具体的性能特征:

订单信息:

【公司名称】 广州健仑生物科技有限公司
【】   
【】
【电子邮件】 Service@jianlun.com
【腾讯 】 712628584 712628583
【公司】 www.jianlun。。ｃｏｍ
【公司地址】 广州市清华科技园创新基地番禺石楼镇创启路63号二期2幢首层

Malaria

Malaria is a life-threatening disease, which is caused by the protozoon Plasmodium spp. The transmission is mediated by the Anopheles mosquito, but can occur via blood transfusion also. Humans can be infected by four different species of Plasmodium: P. falciparum, P. vivax, P. ovale and P. malariae.

Infections with P. falciparum can be deadly. P. falciparum and P. vivax are the most common types. The disease occurs mainly in tropical and subtropical areas.

The Malaria infection induces the production of specific antibodies. In general they can be detected within some days after the occurrence of the parasites in the blood. The concentration of the specific antibodies is proportional to the intensity and duration of infection. The detection of antibodies is more sensitive than the direct detection of the pathogen and independent of the status of the infection. In humans who are infected for the first time the level of the specific antibodies decreases fast after recuperation. In contrast the antibody level decreases slowly (within 2 ? 3 years) in re-infected persons who move into non-endemic areas.

The NovaLisa? Malaria antibody assay is a fast and sensitive enzyme immunoassay for the detection of specific IgG and IgM antibodies against Plasmodium spp.

The microplate is coated with recombinant antigens of P. falciparum and P. vivax. P. ovale and P. malaria are also detected due to the antigenic similarity between the different Plasmodium species.

Infections may be diagnosed by:

Microscopy: Direct detection and indentification of the pathogen is possible but uncertain

Serology: Determination of specific antibodies based on the ELISA-technique

NovaLisa^TM Malaria ELISA:

The NovaLisa^TM Malaria ELISA is intended for the qualitative determination of antibodies against Plasmodium in human serum or plasma (citrate).

Principal of the Assay

The qualitative immunoenzymatic determination of antibodies against Plasmodium is based on the ELISA (Enzyme-linked Immunosorbent Assay) technique.

Microtiter strip wells re pre-coated with Plasmodium antigens to bind corresponding antibodies of the specimen. After washing the wells to remove all unbound sample material hoseradish peroxidase (HRP) labeled anti-human IgG and IgM conjugate are added. This conjugate binds to the capture Plasmodium-specific antibodies.

The immune complecx formed by the bound conjugate is visualized by adding Tetramethylbenzidine (TMB) substrate, which gives a blue reaction product. The intensity of this product is proportional to the amount of Plasmodium-specific antibodies in the specimen. Sulphuric acid is added to stop the reaction. This produces a yellow endpoint color. Absorbance at 450 nm is read using an ELISA microwell plate reader.

Recombinant Antigen:

Recombinant CSP and MSP1 proteins from Plasmodium vivax and Plasmodium falciparum

Specific performance characteristics:

Order information: